Camptothecin and its analogues: a review on their chemotherapeutic potential

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Natural Products

Background:

• Topoisomerase I (Topo-I) is a critical target for developing novel anticancer therapeutics.
• Topo-I inhibitors represent a significant class of existing anticancer medications.
• Camptothecin (CPT), derived from Camptotheca acuminata, is the foundational structure for clinically evaluated Topo-I inhibitors.

Purpose of the Study:

• To comprehensively review the phytochemical aspects of camptothecin (CPT).
• To analyze various structural modifications of CPT across its A, B, C, D, and E rings.
• To discuss non-anticancer biological activities of CPT reported up to 2003.

Main Methods:

• Literature review of phytochemical data.
• Analysis of structure-activity relationships based on CPT modifications.
• Compilation of reported biological activities beyond anticancer effects.

Main Results:

• CPT exhibits significant antitumor activity against lung, ovarian, breast, pancreas, and stomach cancers.
• Detailed review of CPT's phytochemical profile and structural variations.
• Exploration of CPT's diverse biological effects beyond its anticancer properties.

Conclusions:

• Camptothecin analogues are vital in Topoisomerase I-targeted cancer therapy.
• Understanding CPT's structure and activity is key for anticancer drug design.
• CPT possesses a range of biological activities warranting further investigation.